Diabetic NephropathyNCT06927921
Assessement of the Knoweldge ,Attitudes,Practices of Diabetic Kidney Disease Among Diabetic Patients
An observational study of Diabetic Nephropathy, run by Assiut University at 2 sites in Egypt.
Trial summary
This research aims to evaluate the levels of knowledge , attitudes and practices, of diabetic kidney disease among diabetic patients. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Diabetic Nephropathy
- How many people
- 400 participants
- Where
- 2 sitesEgypt
- Study dates
- Apr 2025to May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: Across sectional study take anumber of diabetic patients either type 1or 2DM with age above 18yrs old to evaluate the level of knoweldge,attitudes and practices of diabetic kidney disease.
Who may be able to join
- • Diabetic patients (either type 1or 2 DM ) with age above 18yrs old.
Who cannot join
- • CKD patients due to cause other than diabetes.
- Patients who refuse participation in the study.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt2 sites
Assuit university
Assuit University
Assuit university
Asyut
Sara Abdelaziz Hassan Mahmoud, resident doctor, 01013619689, s010136196892@gmail.com
About this study
Official title: Assessemnt of the Knoweldge ,Attitudes and Practices of Diabetic Kidney Disease Among Diabetic Patients
This research aims to evaluate the levels of knowledge , attitudes and practices, of diabetic kidney disease among diabetic patients.
Read the detailed description
Diabetic kidney disease is defined as patients with diabetes mellitus who have persistent proteinuria for at least three consecutive measurements per year, or a decrease in GFR (<90 ml/min/1.73m²) .Diabetic kidney disease is a severe microvascular complication frequently associated with both type 1 and type 2 diabetes mellitus, is a leading cause of renal failure. The condition can also lead to accelerated cardiovascular disease and macrovascular complications.
In Egypt, DM is a dilemma and a fast-expanding concern. According to the International Diabetes Federation (IDF), the prevalence of DM among Egyptian adults is 15.2%, which may be an underestimation.Public awareness, knowledge, and preventive practices are crucial in mitigating the onset and progression of diabetic nephropathy. Gaining insights into the general population's awareness, knowledge, attitudes, and practices (A-KAP) pertaining to this condition is crucial for the development of effective educational campaigns and preventative strategies.
- Conditions
- Diabetic Nephropathy
- Medical subject headings
- Diabetic Nephropathies
What is being measured
The primary outcome is the main question the study is designed to answer.
evaluation of the knowledge, attitude and practice of chronic kidney disease among the diabetic patients through a questionnaire
CKD screening index, which is divided into three different scales. The knowledge scale consists of 24 items regarding general knowledge of CKD, including its definition, risk factors, signs, symptoms, and complications. The attitudes scale, composed of 15 items, was used to assess the attitudes of diabetic patients toward CKD signs and symptoms and the ability to seek appropriate social and medical help related to their concerns. The practice score consists of 12 items that evaluate the health practices of each patient to prevent CKD. The validity and reliability of this screening index were examined and guaranteed and used in its arabic edition in another study .
The correct answer was given one point, zero points for an incorrect answer, a Therefore, more correct answers meant greater knowledge of DM.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2025
- Study startApr 2025 (estimated)
- Primary completionApr 2026 (estimated)
- Study completionMay 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Diabetic NephropathyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Abdelaziz Hassan Mahmoud, Assiut University
- Investigators
- Salah Abdelazeem Ahmed Seleem, Prof, Principal investigator, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06927921
- Sponsor's protocol ID
- assessment of diabetic kidney
- Status last verified
- Mar 2025
- First submitted
- 28 Mar 2025
- Last updated
- 15 Apr 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Kato M, Natarajan R. Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol. 2014 Sep;10(9):517-30. doi: 10.1038/nrneph.2014.116. Epub 2014 Jul 8.
PubMed 25003613
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessemnt of the Knoweldge ,Attitudes and Practices of Diabetic Kidney Disease Among Diabetic Patients
- ClinicalTrials.gov ID
- NCT06927921
- Acronym / sponsor ID
- assessment of diabetic kidney
- Conditions
- Diabetic Nephropathy
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Apr 2025 (estimated)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- May 2026 (estimated)
- First posted
- 15 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This research aims to evaluate the levels of knowledge , attitudes and practices, of diabetic kidney disease among diabetic patients.
Detailed description
Diabetic kidney disease is defined as patients with diabetes mellitus who have persistent proteinuria for at least three consecutive measurements per year, or a decrease in GFR (<90 ml/min/1.73m²) .Diabetic kidney disease is a severe microvascular complication frequently associated with both type 1 and type 2 diabetes mellitus, is a leading cause of renal failure. The condition can also lead to accelerated cardiovascular disease and macrovascular complications.
In Egypt, DM is a dilemma and a fast-expanding concern. According to the International Diabetes Federation (IDF), the prevalence of DM among Egyptian adults is 15.2%, which may be an underestimation.Public awareness, knowledge, and preventive practices are crucial in mitigating the onset and progression of diabetic nephropathy. Gaining insights into the general population's awareness, knowledge, attitudes, and practices (A-KAP) pertaining to this condition is crucial for the development of effective educational campaigns and preventative strategies.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Across sectional study take anumber of diabetic patients either type 1or 2DM with age above 18yrs old to evaluate the level of knoweldge,attitudes and practices of diabetic kidney disease.
Key inclusion criteria (1 listed)
- • Diabetic patients (either type 1or 2 DM ) with age above 18yrs old.
Key exclusion criteria (2 listed)
- • CKD patients due to cause other than diabetes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
evaluation of the knowledge, attitude and practice of chronic kidney disease among the diabetic patients through a questionnaire
Time frame: Baseline
CKD screening index, which is divided into three different scales. The knowledge scale consists of 24 items regarding general knowledge of CKD, including its definition, risk factors, signs, symptoms, and complications. The attitudes scale, composed of 15 items, was used to assess the attitudes of diabetic patients toward CKD signs and symptoms and the ability to seek appropriate social and medical help related to their concerns. The practice score consists of 12 items that evaluate the health practices of each patient to prevent CKD. The validity and reliability of this screening index were examined and guaranteed and used in its arabic edition in another study . The correct answer was given one point, zero points for an incorrect answer, a Therefore, more correct answers meant greater knowledge of DM.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2025.
- Results publication: PubMed 25003613Kato M, Natarajan R. Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol. 2014 Sep;10(9):517-30. doi: 10.1038/nrneph.2014.116. Epub 2014 Jul 8.
Related trials for Diabetic Nephropathy
Not yet recruitingObservational study
Beta-2-Trace Protein in Diabetic Nephropathy
Diabetic Nephropathy Type 2, Type 2 Diabetes Mellitus
Active, not recruitingObservational study
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Diabetic Nephropathy, Diabetes Mellitus
Active, not recruitingPhase 4
Pentoxifylline in Diabetic Kidney Disease
Diabetic Kidney Disease
Active, not recruitingPhase 2
A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease
Diabetic Kidney Disease (DKD), Type 2 Diabetes
Not yet recruitingObservational study
Relationship Between Insulin Dose and Complications in Type 1 Diabetes
Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Salah Abdelazeem Ahmed Seleem, Prof principal investigator
Assiut University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetic Nephropathy, run by Assiut University at 2 sites in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sara Abdelaziz Hassan Mahmoud, Resident doctor (01013619689, S01013619689@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
evaluation of the knowledge, attitude and practice of chronic kidney disease among the diabetic patients through a questionnaire (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06927921, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2025.